KFAS
HRMY icon

Keating Financial Advisory Services’s Harmony Biosciences HRMY Stock Holding History

Keating Financial Advisory Services’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.17K Buy
32
+31
+3,100% +$978 ﹤0.01% 2126
2026
Q1 		$28 Hold
1
– – ﹤0.01% 2485
2025
Q4 		$37 Buy
+1
New +$33 ﹤0.01% 2172

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Keating Financial Advisory Services's HRMY Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Harmony Biosciences (HRMY) stake by 3,100% in Q2 2026, buying an estimated $978 and bringing the position to 32 shares worth $1.17K. The position accounts for ﹤0.01% of the portfolio, ranked #2126.

Keating Financial Advisory Services first reported a position in HRMY in Q4 2025 and has held it in 3 quarters since. 326 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Keating Financial Advisory Services held 32 shares of Harmony Biosciences worth $1.17K as of Q2 2026.
  • Keating Financial Advisory Services bought 31 Harmony Biosciences shares in Q2 2026, an estimated $978.
  • Harmony Biosciences made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #2126 holding.
  • Keating Financial Advisory Services first reported a position in Harmony Biosciences in Q4 2025 and has held it in 3 quarters since.
  • 326 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.